Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia (Recent-onset)
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.
- Trial name
- NCT01451736
- Testing
- paliperidone palmitate, risperidone
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
Background: In this proposed study, we aim to investigate safety and efficacy of two synthetic retinoids - bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognition
- Trial name
- NCT00534898
- Testing
- Bexarotene, Fenretinide
- Where
- Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Schizoaffective Disorder
Trial of Cognitive Behavioral Therapy for Schizophrenia
The following study addresses the hypothesis that cognitive-behavioral interventions will be effective in reducing positive and negative symptoms of schizophrenia under the conditions of the German health care system.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00300651
- Testing
- Cognitive Behavioral Therapy
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Philipps University Marburg
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Patient Treated With Lithium, With Bipolar or Schizo-affective Disorder, Hospitalized in a Psychiatric Ward
Validation of the French Version of the Lithium Knowledge Test (LKT)
Lithium is a drug used to treat several psychiatric illnesses. This medication requires particular vigilance because it has a narrow therapeutic margin: the dose necessary to obtain an effective treatment is close to the toxic…
- Trial name
- LKT (NCT06033326)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille
Schizophrenia, Schizoaffective Disorder
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia.
- Trial name
- OTS-12WK (NCT01394471)
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognitive Impairment
- Trial name
- Guanfacine (NCT00469664)
- Testing
- Guanfacine/Tenex
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Insomnia, Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life.
- Conditions
- Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
- Trial name
- NCT00645944
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Conversion to Antipsychotic Monotherapy
This is a 12-week, with a 32-week follow-up, rater-blind, randomized controlled trial to determine whether patients with chronic schizophrenia or schizoaffective disorder receiving two different antipsychotics simultaneously will…
- Trial name
- MOPE (NCT01368458)
- Testing
- Conversion to Antipsychotic Monotherapy
- Volunteers
- 24 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an…
- Trial name
- CRC (NCT02476708)
- Testing
- curcumin 1800mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Schizoaffective Disorder
Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT02221635
- Testing
- rTMS + risperidone, Risperidone
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Xijing Hospital
Schizophrenia or Schizoaffective Disorder
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
- Trial name
- MAD (NCT02504476)
- Testing
- AMG 581, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia, Schizoaffective Disorder
Zyprexa and Task Engagement in Schizophrenia
Individuals with schizophrenia frequently have impairments in attention. These impairments have been shown to be related to overall functioning.
- Trial name
- NCT00440843
- Testing
- Olanzapine (Zyprexa), Typicals
- Where
- United States
- Sponsor
- VA Connecticut Healthcare System
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder, Schizoaffective Disorder
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study.
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania
- Trial name
- NCT00431184
- Testing
- Pentazocine, Lorazepam
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mclean Hospital
Psychotic Disorder, Schizophreniform Disorder
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
Weight gain associated with antipsychotic medication use is a major side effect that limits the tolerability of these drugs. This often significant weight gain adversely affects health, increasing risks for developing…
- Conditions
- Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00287352
- Testing
- Olanzapine, Amantadine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory Hallucination
Schizophrenia is a severe neuropsychiatric disorder of the brain and is also one of the top ten disabling diseases. A common symptom of schizophrenia (SCZ) is hearing voices inside one's heads which others do not.
- Trial name
- NCT04629352
- Testing
- Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)
- Where
- India
- Volunteers
- 72 people
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Schizophrenia
Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia
This study will evaluate the effectiveness of a lifestyle intervention in increasing physical activity and reducing disease symptoms in sedentary adults with schizophrenia.
- Trial name
- NCT00338832
- Testing
- Physically Ready for Invigorating Movement Every Day (PRIME), Program for Activity, Leisure Skills, and Socialization (PALSS)
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Schizoaffective Disorder
eMove - Dance/Movement Therapy Study
Schizophrenia is a chronic and severe mental disorder affecting 20 million people throughout the world and is the fourth leading cause of disability in the developed world.
- Trial name
- NCT05712928
- Testing
- Dance/movement therapy (eMove)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Drexel University